undamentalytics Newsletter
Sign in

ADC Therapeutics SA income statement

In fiscal 2025, ADC Therapeutics SA reported revenue of $81.4m, up 14.9% on the year before, operating income of −$121m (a -149.3% margin) and net income of −$143m, or −$1.12 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue21070718180
Cost of revenue3366—
Gross profit207676576—
Research and development18612711010482
Selling and marketing6957444348
General and administrative7448423737
Operating income−123−166−131−121−100
Interest expense3746505252
Income before tax−147−195−156−142−97
Income tax03901−0
Net income−157−240−158−143−97
Diluted EPS−$2.01−$2.94−$1.62−$1.12−$0.65
Diluted shares (average)78m82m97m127m149m
EBITDA−122−165−129−121—

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AAPG vs ADCTADCT vs PLXADCT vs BCYC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from ADC Therapeutics SA's SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to ADC Therapeutics SA.